While generally considered safe, semaglutide may be less effective for patients with MASH who dont also have obesity or diabetes, poses specific risks for older adults (like muscle loss and side effects), and isnt approved for children or teens or for those navigating severe complications like cirrhosis
Adjusting the dose or modifying lifestyle habits may help improve outcomes
Tirzepatide (Mounjaro) has shown slightly better weight loss results than semaglutide (Ozempic/Wegovy) in clinical trials
The clients who feel the most dramatic improvements usually also prioritize sleep, manage stress, and maintain decent eating habits
They advertise IV drips, red light therapy, cryotherapy and hyperbaric chambers
And it helps you identify patterns